News

Altimmune shares slump as weight-loss drug's fatty liver trial data disappoints
Altimmune shares cratered more than 50% on Thursday after its experimental obesity drug did not significantly improve liver ...
Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra
Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) is one of the best biotech stocks to invest in now. On June 20, Madrigal ...
Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperforms
Madrigal Pharma's REZDIFFRA sees 33% Q1 2025 sales growth, strong EU progress, and promising MASH data. Read why I maintain ...
Pharmabiz5d
EMA committee recommends approval of Madrigal Pharma’s resmetirom to treat MASH with moderate to advanced liver fibrosis
Conshohocken, Pennsylvania Monday, June 23, 2025, 13:30 Hrs [IST] ...
EU regulator backs conditional authorisation for Madrigal's liver disease drug
The European Union's drug regulator on Friday recommended conditional authorisation of Madrigal Pharmaceuticals' Rezdiffra, ...
European Advisory Panel Backs Conditional Approval For Madrigal's Fatty Liver Disease Drug
Rezdiffra wins CHMP backing for conditional EU approval in MASH with fibrosis; decision from European Commission expected in August.
Pharmaceutical Technology7d
Madrigal poised to enter European MASH market after CHMP endorsement
Revenue for Madrigal’s Rezdiffra, already approved in the US, is expected to skyrocket over the coming decade.
pharmaphorum7d
Madrigal closes on EU approval of first MASH treatment
Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a treatment for metabolic ...
Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval
Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease ...
Gut8d
Non-invasive risk-based surveillance of hepatocellular carcinoma in patients with metabolic dysfunction-associated steatotic liver disease
Background Metabolic dysfunction-associated steatotic liver disease (MASLD) affects over 30% of the general population and is ...
Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated ...
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it ...